Comparison of the Influence of Five Cannabidiol Formulations on Kidney and Liver Function

Voiceover

Presenter(s)

Matthew Bomar

Abstract or Description

With the increased usage of Cannabidiol (CBD) in the American public, research and clinical trials have gone underway to determine the potential physiological effects of CBD. While some research and clinical trials have found that regular CBD usage has negative effects on the liver and kidney, other research has determined that CBD might relieve symptoms of people with chronic liver and kidney disease. The purpose of this study was to investigate the properties of CBD, and its influence on kidney and liver health. Adult men (n=14) with overweight or obesity (determined by Body Mass Index, >25kg/m²) imbibed 5 different CBD formulations (725, 126, 625, 088, and 213) in a randomized crossover design. Each CBD formulation possessed 30 mg of CBD powder or oil dissolved or mixed into water. Circulating factors to determine kidney and liver health were analyzed with comprehensive metabolic panels via chemical analysis. Some CBD formulations were found to significantly increase albumin (088 and 725) and total bilirubin (625, 213, 126, and 725). However, the increase for these circulating factors were still within a physiologically safe range, indicating that CBD caused no harm or benefit to liver and kidney function.

Mentor

Dr. Christopher Bell